metronidazole has been researched along with Innate Inflammatory Response in 65 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this work was to assess the effect of broadspectrum antibiotics - combination of metronidazole and ciprofloxacin or metronidazole alone - on the intensity of intraocular inflammation in experimental autoimmune uveitis (EAU)." | 7.91 | Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis. ( Dusek, O; Heissigerova, J; Klimova, A; Kucera, T; Seidler Stangova, P; Svozilkova, P, 2019) |
| "Metronidazole is clinically effective in treating not only rosacea but also acne inflammation." | 7.68 | The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. ( Akamatsu, H; Asada, Y; Nishijima, S; Niwa, Y; Oguchi, M; Takahashi, M; Ushijima, T, 1990) |
| "BackgroundBacterial vaginosis (BV) causes genital inflammation and increases HIV risk, whereas a vaginal microbiota dominated by Lactobacillus species is associated with immune quiescence and relative HIV protection." | 7.11 | Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli. ( Armstrong, E; Burke, KE; Castañeda, GR; Coburn, B; Cohen, CR; Crawford, ED; Hemmerling, A; Huibner, S; Kaul, R; Kulikova, M; Liu, R; Miller, S; Morris, SR; Nagelkerke, N; Newmann, SJ; Reno, H, 2022) |
| "Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities." | 5.91 | Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice. ( Cao, M; Chen, Q; He, Z; Huang, M; Qing, L; Wu, C; Yan, X; Yu, Z; Zhang, X; Zhao, J; Zhao, Q, 2023) |
| "Subjects in the tetracycline and triple therapy groups, but not the calcium carbonate only group, showed a reduction in inflammation and epithelial damage vs." | 5.09 | Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. ( Bravo, JC; Bravo, LE; Casabon, AL; Collazos, T; Correa, P; Fischbach, LA; Ramirez, H; Realpe, JL; Ruiz, B; Schmidt, BA, 2001) |
| " The aim of this work was to assess the effect of broadspectrum antibiotics - combination of metronidazole and ciprofloxacin or metronidazole alone - on the intensity of intraocular inflammation in experimental autoimmune uveitis (EAU)." | 3.91 | Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis. ( Dusek, O; Heissigerova, J; Klimova, A; Kucera, T; Seidler Stangova, P; Svozilkova, P, 2019) |
| " We measured biomarkers of subclinical vaginal inflammation, endogenous antimicrobial activity, and vaginal flora in women with BV and repeated sampling 1 week and 1 month after completion of metronidazole therapy." | 3.81 | Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. ( Anderson, S; Chandra, N; Cunningham, TD; Dawood, HY; Doncel, G; Fashemi, T; Fichorova, RN; Herold, B; Kimble, T; Mesquita, PM; Rabe, L; Schwartz, J; Thurman, AR, 2015) |
| "The anti-inflammatory effect of azithromycin did not differ from the effect of methylprednisolone, when compared with control group with experimental colitis." | 3.76 | Effect of azithromycin on acute inflammatory lesions and colonic bacterial load in a murine model of experimental colitis. ( Anić, B; Banić, M; Brkić, T; Plecko, V; Plesko, S; Renata, H; Rotkvić, I, 2010) |
| "In patients with persisting symptoms after metronidazole treated Giardia infection we commonly found chronic Giardia infection and microscopic duodenal inflammation, especially in illness duration less than 7 months." | 3.74 | Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. ( Coll, P; Hanevik, K; Hausken, T; Helgeland, L; Langeland, N; Morken, MH; Mørch, K; Strand, EA, 2007) |
| "The penicillin-metronidazole combination is well tried antibiotic therapy for the treatment of inflammations of dental origin." | 3.69 | [The role of dalacin C in the management of odontogenic inflammations]. ( Gyenes, V; Sülle, T, 1995) |
| "Metronidazole is clinically effective in treating not only rosacea but also acne inflammation." | 3.68 | The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. ( Akamatsu, H; Asada, Y; Nishijima, S; Niwa, Y; Oguchi, M; Takahashi, M; Ushijima, T, 1990) |
| "BackgroundBacterial vaginosis (BV) causes genital inflammation and increases HIV risk, whereas a vaginal microbiota dominated by Lactobacillus species is associated with immune quiescence and relative HIV protection." | 3.11 | Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli. ( Armstrong, E; Burke, KE; Castañeda, GR; Coburn, B; Cohen, CR; Crawford, ED; Hemmerling, A; Huibner, S; Kaul, R; Kulikova, M; Liu, R; Miller, S; Morris, SR; Nagelkerke, N; Newmann, SJ; Reno, H, 2022) |
| "Biofilms on oral squamous cell carcinomas are enriched with anaerobic periodontal pathogens, including F." | 2.72 | Fusobacterium nucleatum and oral cancer: a critical review. ( Craig, SG; James, JA; Linden, GJ; Lundy, FT; McIlvanna, E, 2021) |
| "Metronidazole has been used to treat pouchitis, but there are no controlled data that show it is effective." | 2.67 | Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. ( Madden, MV; McIntyre, AS; Nicholls, RJ, 1994) |
| "Vaginitis is one of the most common causes of patient visits to gynecologists, primary care providers, and urgent care centers." | 2.66 | Noncandidal vaginitis: a comprehensive approach to diagnosis and management. ( Eckert, LO; Kus, LH; Neal, CM; Peipert, JF, 2020) |
| " At present, subantimicrobial dosing of a tetracycline agent that also maintains anti-inflammatory activity has only been established with doxycycline." | 2.48 | Optimal management of papulopustular rosacea: rationale for combination therapy. ( Bhatia, ND; Del Rosso, JQ, 2012) |
| "Metronidazole (MTZ) is a nitroimidazole antibiotic used mainly for the treatment of infections caused by susceptible organisms, particularly anaerobic bacteria and protozoa." | 2.47 | Metronidazole and the immune system. ( Ashraf, M; Javeed, A; Riaz, A; Shakir, L, 2011) |
| "Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities." | 1.91 | Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice. ( Cao, M; Chen, Q; He, Z; Huang, M; Qing, L; Wu, C; Yan, X; Yu, Z; Zhang, X; Zhao, J; Zhao, Q, 2023) |
| "Gingiva samples from untreated chronic periodontitis patients revealed a diffuse positive reaction for MMP-2 in the epithelium and also in fibroblasts and macrophages from the lamina propria." | 1.42 | Effects of therapy with two combinations of antibiotics on the imbalance of MMP-2÷TIMP-2 in chronic periodontitis. ( BaniŢă, IM; Bătăiosu, M; Dăguci, C; Dăguci, L; Pascu, EI; Pisoschi, CG; Taisescu, CI; Ţuculină, MJ, 2015) |
| "Metronidazole treatment amplified these proinflammatory responses." | 1.38 | Endobiont viruses sensed by the human host - beyond conventional antiparasitic therapy. ( Beach, DH; Buck, OR; Chepa-Lotrea, X; Fichorova, RN; Goodman, RP; Hayes, GR; Kula, T; Lee, Y; Murray, R; Nibert, ML; Singh, BN; Takagi, Y; Yamamoto, HS, 2012) |
| "Periodontitis is a well-appreciated example of leukocyte-mediated bone loss and inflammation that has pathogenic features similar to those observed in other inflammatory diseases such as arthritis." | 1.33 | RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. ( Arita, M; Chiang, N; Ebrahimi, N; Hasturk, H; Kantarci, A; Levy, BD; Ohira, T; Petasis, NA; Serhan, CN; Van Dyke, TE, 2006) |
| "Metronidazole was more potent than amoxicillin/clavulanic acid and anti-tumour necrosis factor in improving the indometacin-induced small bowel inflammation." | 1.31 | Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model. ( Ceuppens, JL; Colpaert, S; De Greef, B; Geboes, K; Liu, Z; Rutgeerts, P, 2001) |
| "Antibiotics used for the treatment of acne significantly inhibited ROS generated by neutrophils, when compared to other antibiotics." | 1.30 | The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. ( Akamatsu, H; Horio, T, 1998) |
| "In 7 metronidazole-treated hamsters, no obvious pathological damage was seen." | 1.29 | Monoclonal antibody-based immunohistochemical demonstration of Entamoeba histolytica in liver tissues of experimentally infected hamster (Mesocricetus auratus). ( Punpoowong, B; Riganti, M; Sherchand, JB; Thammapalerd, N; Tharavanij, S, 1994) |
| "Pneumatosis cystoides intestinalis was a sequal in two patients." | 1.26 | Bypass enteropathy: an inflammatory process in the excluded segment with systemic complications. ( Ament, ME; Drenick, EJ; Finegold, SM; Passaro, E, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (13.85) | 18.7374 |
| 1990's | 16 (24.62) | 18.2507 |
| 2000's | 11 (16.92) | 29.6817 |
| 2010's | 22 (33.85) | 24.3611 |
| 2020's | 7 (10.77) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Ali, EMH | 1 |
| Abdel-Maksoud, MS | 1 |
| Oh, CH | 1 |
| Langner, CA | 1 |
| Ortiz, AM | 1 |
| Flynn, JK | 1 |
| Kendall, H | 1 |
| Lagenaur, LA | 1 |
| Brenchley, JM | 1 |
| McIlvanna, E | 1 |
| Linden, GJ | 1 |
| Craig, SG | 1 |
| Lundy, FT | 1 |
| James, JA | 1 |
| Armstrong, E | 2 |
| Hemmerling, A | 2 |
| Miller, S | 2 |
| Burke, KE | 2 |
| Newmann, SJ | 2 |
| Morris, SR | 2 |
| Reno, H | 2 |
| Huibner, S | 2 |
| Kulikova, M | 2 |
| Liu, R | 1 |
| Crawford, ED | 1 |
| Castañeda, GR | 1 |
| Nagelkerke, N | 2 |
| Coburn, B | 2 |
| Cohen, CR | 2 |
| Kaul, R | 2 |
| Yu, Z | 1 |
| Zhang, X | 1 |
| Zhao, Q | 1 |
| Yan, X | 1 |
| Wu, C | 1 |
| Qing, L | 1 |
| He, Z | 1 |
| Chen, Q | 1 |
| Huang, M | 1 |
| Zhao, J | 1 |
| Cao, M | 1 |
| Neal, CM | 1 |
| Kus, LH | 1 |
| Eckert, LO | 1 |
| Peipert, JF | 1 |
| Seidler Stangova, P | 1 |
| Dusek, O | 1 |
| Klimova, A | 1 |
| Heissigerova, J | 1 |
| Kucera, T | 1 |
| Svozilkova, P | 1 |
| Kayal, M | 1 |
| Bhagya Rao, B | 1 |
| Bhattacharya, A | 1 |
| Ungaro, R | 1 |
| Okamoto, K | 1 |
| Watanabe, T | 1 |
| Komeda, Y | 1 |
| Okamoto, A | 1 |
| Minaga, K | 1 |
| Kamata, K | 1 |
| Yamao, K | 1 |
| Takenaka, M | 1 |
| Hagiwara, S | 1 |
| Sakurai, T | 1 |
| Tanaka, T | 1 |
| Sakamoto, H | 1 |
| Fujimoto, K | 1 |
| Nishida, N | 1 |
| Kudo, M | 1 |
| Soto, M | 1 |
| Herzog, C | 1 |
| Pacheco, JA | 1 |
| Fujisaka, S | 1 |
| Bullock, K | 1 |
| Clish, CB | 1 |
| Kahn, CR | 1 |
| Del Rosso, JQ | 2 |
| Gallo, RL | 1 |
| Tanghetti, E | 1 |
| Webster, G | 1 |
| Thiboutot, D | 1 |
| Nahidi, L | 1 |
| Leach, ST | 1 |
| Mitchell, HM | 1 |
| Kaakoush, NO | 1 |
| Lemberg, DA | 1 |
| Munday, JS | 1 |
| Huinao, K | 1 |
| Day, AS | 1 |
| Steven Esworthy, R | 1 |
| Kim, BW | 1 |
| Wang, Y | 1 |
| Gao, Q | 1 |
| Doroshow, JH | 1 |
| Leto, TL | 1 |
| Chu, FF | 1 |
| Bătăiosu, M | 1 |
| Taisescu, CI | 1 |
| Pisoschi, CG | 1 |
| Pascu, EI | 1 |
| Ţuculină, MJ | 1 |
| Dăguci, L | 1 |
| Dăguci, C | 1 |
| BaniŢă, IM | 1 |
| Thurman, AR | 1 |
| Kimble, T | 1 |
| Herold, B | 1 |
| Mesquita, PM | 1 |
| Fichorova, RN | 2 |
| Dawood, HY | 1 |
| Fashemi, T | 1 |
| Chandra, N | 1 |
| Rabe, L | 1 |
| Cunningham, TD | 1 |
| Anderson, S | 1 |
| Schwartz, J | 1 |
| Doncel, G | 1 |
| Kopper, JJ | 1 |
| Patterson, JS | 1 |
| Mansfield, LS | 1 |
| Peretz, A | 1 |
| Tkhawkho, L | 1 |
| Pastukh, N | 1 |
| Brodsky, D | 1 |
| Halevi, CN | 1 |
| Nitzan, O | 1 |
| Huang, TY | 1 |
| Chu, HC | 1 |
| Lin, YL | 1 |
| Lin, CK | 1 |
| Hsieh, TY | 1 |
| Chang, WK | 1 |
| Chao, YC | 1 |
| Liao, CL | 1 |
| Plesko, S | 1 |
| Banić, M | 1 |
| Plecko, V | 1 |
| Anić, B | 1 |
| Brkić, T | 1 |
| Renata, H | 1 |
| Rotkvić, I | 1 |
| Gen, R | 1 |
| Demir, M | 1 |
| Ataseven, H | 1 |
| Gray, C | 1 |
| Loynes, CA | 1 |
| Whyte, MK | 1 |
| Crossman, DC | 1 |
| Renshaw, SA | 1 |
| Chico, TJ | 1 |
| Brandon, JA | 1 |
| Jennings, CD | 1 |
| Kaplan, AM | 1 |
| Bryson, JS | 1 |
| Shakir, L | 1 |
| Javeed, A | 1 |
| Ashraf, M | 1 |
| Riaz, A | 1 |
| Tursi, A | 1 |
| Elisei, W | 1 |
| Brandimarte, G | 1 |
| Giorgetti, GM | 1 |
| Inchingolo, CD | 1 |
| Nenna, R | 1 |
| Picchio, M | 1 |
| Giorgio, F | 1 |
| Ierardi, E | 1 |
| Bhatia, ND | 1 |
| Al-Banna, NA | 1 |
| Pavlovic, D | 1 |
| Gründling, M | 1 |
| Zhou, J | 1 |
| Kelly, M | 1 |
| Whynot, S | 1 |
| Hung, O | 1 |
| Johnston, B | 1 |
| Issekutz, TB | 1 |
| Kern, H | 1 |
| Cerny, V | 1 |
| Lehmann, Ch | 1 |
| Li, HW | 1 |
| Sachs, J | 1 |
| Pichardo, C | 1 |
| Bronson, R | 1 |
| Zhao, G | 1 |
| Sykes, M | 1 |
| Lee, Y | 1 |
| Yamamoto, HS | 1 |
| Takagi, Y | 1 |
| Hayes, GR | 1 |
| Goodman, RP | 1 |
| Chepa-Lotrea, X | 1 |
| Buck, OR | 1 |
| Murray, R | 1 |
| Kula, T | 1 |
| Beach, DH | 1 |
| Singh, BN | 1 |
| Nibert, ML | 1 |
| Chuang, CH | 1 |
| Sheu, BS | 1 |
| Huang, AH | 1 |
| Yang, HB | 1 |
| Wu, JJ | 1 |
| Skerk, V | 1 |
| Schönwald, S | 1 |
| Granić, J | 1 |
| Krhen, I | 1 |
| Barsić, B | 1 |
| Mareković, I | 1 |
| Roglić, S | 1 |
| Desnica, B | 1 |
| Zeljko, Z | 1 |
| Evans, SM | 1 |
| Whittle, BJ | 1 |
| TEOKHAROV, BA | 1 |
| ANIKIN, AF | 1 |
| KLINYSHKOVA, VM | 1 |
| SCHAPIRA, HE | 1 |
| Lindow, KB | 1 |
| Hasturk, H | 1 |
| Kantarci, A | 1 |
| Ohira, T | 1 |
| Arita, M | 1 |
| Ebrahimi, N | 1 |
| Chiang, N | 1 |
| Petasis, NA | 1 |
| Levy, BD | 1 |
| Serhan, CN | 1 |
| Van Dyke, TE | 1 |
| Kularatne, SA | 1 |
| Kumarasiri, PV | 1 |
| Pushpakumara, SK | 1 |
| Dissanayaka, WP | 1 |
| Ariyasena, H | 1 |
| Gawarammana, IB | 1 |
| Senanayake, N | 1 |
| Hanevik, K | 1 |
| Hausken, T | 1 |
| Morken, MH | 1 |
| Strand, EA | 1 |
| Mørch, K | 1 |
| Coll, P | 1 |
| Helgeland, L | 1 |
| Langeland, N | 1 |
| Lo, SF | 1 |
| Hsu, MY | 1 |
| Hu, WY | 1 |
| Russell, RJ | 1 |
| Haines, DC | 1 |
| Anver, MR | 1 |
| Battles, JK | 1 |
| Gorelick, PL | 1 |
| Blumenauer, LL | 1 |
| Gonda, MA | 1 |
| Ward, JM | 1 |
| Sherchand, JB | 1 |
| Thammapalerd, N | 1 |
| Riganti, M | 1 |
| Tharavanij, S | 1 |
| Punpoowong, B | 1 |
| Nygaard, K | 1 |
| Bergan, T | 1 |
| Bjørneklett, A | 1 |
| Høverstad, T | 1 |
| Lassen, J | 1 |
| Aase, S | 1 |
| Keighley, MR | 2 |
| Kelly, KA | 1 |
| Mignon, M | 1 |
| Stettler, C | 1 |
| Phillips, SF | 1 |
| Madden, MV | 1 |
| McIntyre, AS | 1 |
| Nicholls, RJ | 1 |
| Svaninger, G | 1 |
| Nordgren, S | 1 |
| Oresland, T | 1 |
| Hultén, L | 1 |
| Chaussade, S | 1 |
| Kmiot, WA | 1 |
| Hesslewood, SR | 1 |
| Smith, N | 1 |
| Thompson, H | 1 |
| Harding, LK | 1 |
| Gyenes, V | 1 |
| Sülle, T | 1 |
| Hurst, RD | 1 |
| Molinari, M | 1 |
| Chung, TP | 1 |
| Rubin, M | 1 |
| Michelassi, F | 1 |
| Akamatsu, H | 2 |
| Horio, T | 1 |
| Fischbach, LA | 1 |
| Correa, P | 1 |
| Ramirez, H | 1 |
| Realpe, JL | 1 |
| Collazos, T | 1 |
| Ruiz, B | 1 |
| Bravo, LE | 1 |
| Bravo, JC | 1 |
| Casabon, AL | 1 |
| Schmidt, BA | 1 |
| Colpaert, S | 1 |
| Liu, Z | 1 |
| De Greef, B | 1 |
| Rutgeerts, P | 1 |
| Ceuppens, JL | 1 |
| Geboes, K | 1 |
| Drenick, EJ | 1 |
| Ament, ME | 1 |
| Finegold, SM | 1 |
| Passaro, E | 1 |
| Donaldson, M | 1 |
| Heyneman, D | 1 |
| Dempster, R | 1 |
| Garcia, L | 1 |
| Füllner, G | 1 |
| Müller, W | 1 |
| Rauh, SM | 1 |
| Schoetz, DJ | 1 |
| Roberts, PL | 1 |
| Murray, JJ | 1 |
| Coller, JA | 1 |
| Veidenheimer, MC | 1 |
| Oguchi, M | 1 |
| Nishijima, S | 1 |
| Asada, Y | 1 |
| Takahashi, M | 1 |
| Ushijima, T | 1 |
| Niwa, Y | 1 |
| McLeod, RS | 1 |
| Taylor, DW | 1 |
| Cohen, Z | 1 |
| Cullen, JB | 1 |
| Aronson, IK | 1 |
| Rumsfield, JA | 1 |
| West, DP | 1 |
| Alexander, J | 1 |
| Fischer, JH | 1 |
| Paloucek, FP | 1 |
| Miller, B | 1 |
| Martini, GA | 1 |
| Antani, J | 1 |
| Srinivas, HV | 1 |
| Krishnamurthy, KR | 1 |
| Jahagirdar, BR | 1 |
| Jansen, GT | 1 |
| Morgan, PN | 1 |
| McQueen, JN | 1 |
| Bennett, WE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis[NCT02766023] | Phase 2 | 228 participants (Actual) | Interventional | 2016-06-03 | Completed | ||
| Effects of Nutrients Supplementation in Antidepressant Treated Depressive Disorder Patients[NCT04179006] | 120 participants (Anticipated) | Interventional | 2019-11-14 | Recruiting | |||
| Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea[NCT04491799] | 135 participants (Actual) | Observational | 2019-02-01 | Completed | |||
| Efficacy of the Use of Metronidazole After Laparoscopic Hysterectomy for the Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess. Multicentric Triple-blind Randomized Controlled Trial[NCT03917134] | 600 participants (Anticipated) | Interventional | 2019-05-01 | Not yet recruiting | |||
| Routine vs. Clinically-Directed Antibiotic Treatment in Snake Bite With Local Envenomation: a Randomised Controlled Trial[NCT02570347] | Phase 4 | 130 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Tolerability of LACTIN-V and the applicator was measured by the proportion of participants who discontinued the study product prior to completing the dose schedule due to an adverse event. (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | Participants (Count of Participants) |
|---|---|
| LACTIN-V | 1 |
| Placebo | 0 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | percentage of participants (Number) |
|---|---|
| LACTIN-V | 0.85 |
| Placebo | 0.07 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 1 to Day 168
| Intervention | percentage of participants (Number) |
|---|---|
| LACTIN-V | 0.86 |
| Placebo | 0.08 |
"Adverse events and serious adverse events were collected during the entire study period. Relatedness to study product was assessed by the site investigator according to the protocol definition of related as There is a reasonable possibility that the study product caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the AE." (NCT02766023)
Timeframe: Day 1 to Day 168
| Intervention | proportion of participants (Number) |
|---|---|
| LACTIN-V | 0.11 |
| Placebo | 0.07 |
A positive BV diagnosis was defined by at least 3 of the 4 Amsel criteria and a Nugent score of 4-10. Amsel criteria are: homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls; vaginal pH >4.5; positive whiff-amine test, defined as the presence of a fishy odor when a drop of 10% potassium hydroxide is added to a sample of vaginal discharge; and presence of clue cells (>20%) on microscopy. The Nugent score is calculated by assessing for the presence of large Gram-positive rods scored as 0 to 4, small Gram-variable rods scored as 0 to 4, and curved Gram-variable rods scored as 0 to 2. All BV diagnoses following 15 days after enrollment (22 days after commencement of MetroGel treatment) were considered a recurrent episode. (NCT02766023)
Timeframe: Day 1 to Day 168
| Intervention | percentage of participants (Number) |
|---|---|
| LACTIN-V | 0.39 |
| Placebo | 0.54 |
A positive BV diagnosis was defined by meeting at least 3 of the 4 Amsel criteria and a Nugent score of 4-10. Amsel criteria are: homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls; vaginal pH >4.5; positive whiff-amine test, defined as the presence of a fishy odor when a drop of 10% potassium hydroxide is added to a sample of vaginal discharge; and presence of clue cells (>20%) on microscopy. The Amsel score ranges from 0-4, where higher scores mean a worse outcome. The Nugent score is calculated by assessing for the presence of large Gram-positive rods scored as 0 to 4, small Gram-variable rods scored as 0 to 4, and curved Gram-variable rods scored as 0 to 2, and adding all component scores. The Nugent score ranges from 0-10, where higher scores mean a worse outcome. All BV diagnoses following 15 days after enrollment (22 days after commencement of MetroGel treatment) were considered a recurrent episode. (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | proportion of participants (Number) |
|---|---|
| LACTIN-V | 0.30 |
| Placebo | 0.45 |
"Participants answered a detailed self-administered questionnaire at Week 12 assessing the acceptability of the study product and the applicator. Questionnaire items included rating aspects of the product and applicator by various measures, including by rating factors on a 0-10 scale, with 0 being not at all and 10 being extremely." (NCT02766023)
Timeframe: Day 84
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Effectiveness | Comfort | Ease of use | Vaginal health | Other Finding | |
| LACTIN-V | 7.53 | 8.16 | 8.99 | 7.37 | 8.21 |
| Placebo | 6.72 | 8.07 | 8.75 | 7.01 | 9.27 |
"Participants answered a detailed self-administered questionnaire at Week 12 assessing the acceptability of the study product and the applicator. Questionnaire items included rating aspects of the product and applicator by various measures, including by rating factors on use of the product on a 0-10 scale, with 0 being not at all and 10 being extremely so." (NCT02766023)
Timeframe: Day 84
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| High frequency | Vaginal Dryness | Discomfort | Messiness | Disapproval | Other issue | |
| LACTIN-V | 2.97 | 1.71 | 1.53 | 2.10 | 0.98 | 7.08 |
| Placebo | 2.63 | 1.37 | 1.01 | 1.68 | 0.79 | 7.62 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 1
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 0 | 4 |
| Placebo | 0 | 0 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 28
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 37 | 76 |
| Placebo | 1 | 3 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 56
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 28 | 78 |
| Placebo | 0 | 1 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 84
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Condom-less sex acts since last visit | No condom-less sex acts since last visit | |
| LACTIN-V | 38 | 64 |
| Placebo | 0 | 2 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 28
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Menses since last visit | No menses since last visit | |
| LACTIN-V | 93 | 20 |
| Placebo | 3 | 1 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 56
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Menses since last visit | No menses since last visit | |
| LACTIN-V | 76 | 30 |
| Placebo | 1 | 0 |
Colonization of L. crispatus was determined from the concentrations of L. crispatus species and L. crispatus CTV-05 obtained from qPCR. Successful colonization was defined as: If CTV-05 concentration was above the lower limit of detection (LLOD) and the L. crispatus was above the LLOD, then successful colonization had occurred. If either CTV-05 or L. crispatus concentration was below LLOD or indeterminate, then successful colonization had not occurred. The LLOD for CTV-05 was 660 copies/mL and the LLOD for L. crispatus was 953 copies/mL (NCT02766023)
Timeframe: Day 84
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Menses since last visit | No menses since last visit | |
| LACTIN-V | 74 | 28 |
| Placebo | 2 | 0 |
A subject was considered compliant with the assigned study product if she took 4 of the first 5 daily doses and at least 75% of the scheduled doses overall prior to the first diagnosis of BV or through Week 12, whichever occurred first. Compliance was assessed by subject report via the memory aid and, separately, applicator staining of the returned kit. Compliance was assessed on a weekly basis and the time (week) at which the subject became non-compliant was determined by blinded PI review. (NCT02766023)
Timeframe: Day 1 to Day 84
| Intervention | proportion of participants (Number) | |
|---|---|---|
| Self-report | Staining | |
| LACTIN-V | 0.80 | 0.77 |
| Placebo | 0.78 | 0.72 |
Participants answered a detailed self-administered questionnaire at Week 12 assessing the acceptability of the study product and the applicator. Questionnaire items included rating aspects of the product and applicator by Likert-scale responses of strongly agree, agree, neutral, disagree and strongly disagree. (NCT02766023)
Timeframe: Day 84
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I was satisfied overall with vaginal applicator72598130 | I was satisfied overall with vaginal applicator72598131 | Satisfied with comfort of vaginal applicator72598130 | Satisfied with comfort of vaginal applicator72598131 | Satisfied with ease of use of vaginal applicator72598130 | Satisfied with ease of use of vaginal applicator72598131 | Vaginal health improved with study participation72598131 | Vaginal health improved with study participation72598130 | Important I use product without partner knowing72598130 | Important I use product without partner knowing72598131 | Important for me that partner approved of product72598130 | Important for me that partner approved of product72598131 | I would use the product again72598131 | I would use the product again72598130 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Strongly agree | Agree | Neutral | Disagree | Strongly disagree | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 59 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 55 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 63 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 58 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 34 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 72 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LACTIN-V | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
13 reviews available for metronidazole and Innate Inflammatory Response
| Article | Year |
|---|---|
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Chemistry, Ph | 2019 |
Fusobacterium nucleatum and oral cancer: a critical review.
Topics: Animals; Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Cell Movement; Cell Proliferation; Col | 2021 |
Noncandidal vaginitis: a comprehensive approach to diagnosis and management.
Topics: Administration, Intravaginal; Administration, Oral; Anti-Infective Agents; Anti-Inflammatory Agents; | 2020 |
An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea.
Topics: Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Humans; Immunity, Innate; Inflammation; Low-Le | 2013 |
Metronidazole and the immune system.
Topics: Adaptive Immunity; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal Agents; Graf | 2011 |
Optimal management of papulopustular rosacea: rationale for combination therapy.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents; Dermatologic Agents; Dica | 2012 |
Impact of antibiotics on the microcirculation in local and systemic inflammation.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Autophagy; Chemotaxis, Leukocyte; Colitis; | 2013 |
Rosacea. An overview of diagnosis and management.
Topics: Anti-Infective Agents; Body Image; Dermatologic Agents; Diagnosis, Differential; Dicarboxylic Acids; | 2004 |
Using wound bed preparation to heal a malignant fungating wound: a single case study.
Topics: Adult; Bandages, Hydrocolloid; Breast Neoplasms; Carboxymethylcellulose Sodium; Clinical Protocols; | 2007 |
["Pouchitis"; histology].
Topics: Crohn Disease; Diagnosis, Differential; Diarrhea; Fecal Incontinence; Humans; Ileitis; Ileum; Inflam | 1993 |
[Ileo-anal "pouchitis": a still misunderstood pathology].
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Glutamine; Humans; Ileitis; Inflammation; Metronidazol | 1993 |
[Ileoanal anastomosis with pouch: a rigorous surgical technique is necessary, but the most frequent long-term postoperative complication remains inflammation of the pouch].
Topics: Adenomatous Polyposis Coli; Adrenal Cortex Hormones; Colitis, Ulcerative; Diarrhea; Female; Humans; | 1993 |
[What is secured in the therapy of chronic inflammatory colonic diseases?].
Topics: Administration, Topical; Amebiasis; Azathioprine; Chronic Disease; Colitis; Colitis, Ulcerative; Col | 1974 |
10 trials available for metronidazole and Innate Inflammatory Response
| Article | Year |
|---|---|
Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli.
Topics: Bacteria; Female; HIV Infections; Humans; Inflammation; Lactobacillus; Metronidazole; Vagina; Vagino | 2022 |
Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.
Topics: Bacteria; Cadherins; Canada; Female; HIV Infections; Humans; Inflammation; Lactobacillus crispatus; | 2022 |
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; D | 2002 |
Chronic prostatitis caused by Trichomonas vaginalis--diagnosis and treatment.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Drug Administration Schedule; Humans; Inflammation; | 2002 |
Routine antibiotic therapy in the management of the local inflammatory swelling in venomous snakebites: results of a placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Edema; Female; Humans; Inflammation; Lower Ex | 2005 |
Topical metronidazole treatment in pouchitis.
Topics: Adenomatous Polyposis Coli; Administration, Topical; Adolescent; Adult; Colitis, Ulcerative; Fatty A | 1994 |
Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis.
Topics: C-Reactive Protein; Chronic Disease; Colitis, Ulcerative; Defecation; Double-Blind Method; Humans; I | 1994 |
Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Calcium Carbonate; Drug Therapy, | 2001 |
Single-patient randomised clinical trial. Use in determining optimum treatment for patient with inflammation of Kock continent ileostomy reservoir.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Ileostom | 1986 |
Evaluation of topical metronidazole gel in acne rosacea.
Topics: Administration, Topical; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Erythema; Femal | 1987 |
42 other studies available for metronidazole and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
The Vaginal Microbiome of Nonhuman Primates Can Be Only Transiently Altered to Become
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Female; Humans; Inflammation; Lactobacillus cr | 2021 |
Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antioxidants; Clarithromycin; Drug Therapy | 2023 |
Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis.
Topics: Animals; Ciprofloxacin; Female; Inflammation; Metronidazole; Mice, Inbred C57BL; Severity of Illness | 2019 |
Clinical Challenge: From Ulcerative Colitis to Crohn's Disease-Like Pouch Inflammation.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Colitis, Ulcerative; Crohn Di | 2021 |
Dysbiosis-Associated Polyposis of the Colon-Cap Polyposis.
Topics: Ampicillin; Anti-Bacterial Agents; Asymptomatic Diseases; Bacteria; Colon; Colonic Polyps; Dysbiosis | 2018 |
Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism.
Topics: Animals; Anti-Bacterial Agents; Anxiety; Brain; Diet, High-Fat; Gastrointestinal Microbiome; Inflamm | 2018 |
Inflammatory bowel disease therapies and gut function in a colitis mouse model.
Topics: Animals; Colitis; Crohn Disease; Disease Models, Animal; Enteral Nutrition; Helicobacter; Humans; In | 2013 |
The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene.
Topics: Alleles; Animals; Apoptosis; Cell Proliferation; Colitis; Cyclooxygenase 2; Dysbiosis; Epithelial Ce | 2013 |
Effects of therapy with two combinations of antibiotics on the imbalance of MMP-2÷TIMP-2 in chronic periodontitis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Periodontitis; Drug Therapy, Combination; F | 2015 |
Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity.
Topics: Adult; Anti-Infective Agents; Asymptomatic Infections; Biomarkers; Biopsy; Cervix Uteri; Female; Hum | 2015 |
Metronidazole-but not IL-10 or prednisolone-rescues Trichuris muris infected C57BL/6 IL-10 deficient mice from severe disease.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Female; Gene Expression Regulation; Inflam | 2015 |
Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Clostridioides difficile; Clostridium Infect | 2016 |
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Disea | 2009 |
Effect of azithromycin on acute inflammatory lesions and colonic bacterial load in a murine model of experimental colitis.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Colitis; Colon; Inflammation; Male; Methylprednisolone | 2010 |
Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; C-Reactive Prote | 2010 |
Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using a novel transgenic zebrafish.
Topics: Animals; Animals, Genetically Modified; Cell Movement; Embryo Culture Techniques; Endothelium, Vascu | 2011 |
Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.
Topics: Animals; Anti-Bacterial Agents; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Cell Line; | 2011 |
Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Case | 2012 |
Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli.
Topics: Animals; Ciprofloxacin; Graft vs Host Disease; Inflammation; Lymphocyte Transfusion; Lymphopenia; Me | 2012 |
Endobiont viruses sensed by the human host - beyond conventional antiparasitic therapy.
Topics: Animals; Anti-Bacterial Agents; Antiparasitic Agents; Female; Host-Pathogen Interactions; Humans; Im | 2012 |
Role of bacteria and inducible nitric oxide synthase activity in the systemic inflammatory microvascular response provoked by indomethacin in the rat.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2003 |
[EXPERIENCE WITH PERORAL THERAPY OF UROGENITAL TRICHOMONIASIS WITH FLAGYL].
Topics: Cystitis; Female; Humans; Imidazoles; Inflammation; Intraabdominal Infections; Metronidazole; Tricho | 1963 |
STUDIES ON METRONIDAZOLE (FLAGYL) IN THE THERAPY OF UROGENITAL TRICHOMONIASIS IN THE MALE PATIENT.
Topics: Drug Therapy; Genital Diseases, Male; Humans; Inflammation; Male; Metronidazole; Toxicology; Trichom | 1965 |
RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis.
Topics: Administration, Topical; Alveolar Bone Loss; Animals; Eicosapentaenoic Acid; Humans; Inflammation; L | 2006 |
Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection.
Topics: Animals; Biopsy; Cohort Studies; Disease Outbreaks; Duodenitis; Duodenoscopy; Duodenum; Feces; Giard | 2007 |
Use of antibiotics to prevent hepatitis and typhlitis in male scid mice spontaneously infected with Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Cecal Diseases; Cecum; Chronic Disease; Helico | 1995 |
Monoclonal antibody-based immunohistochemical demonstration of Entamoeba histolytica in liver tissues of experimentally infected hamster (Mesocricetus auratus).
Topics: Animals; Antibodies, Monoclonal; Cricetinae; Entamoeba histolytica; Entamoebiasis; Fluorescent Antib | 1994 |
["Pouchitis": new routes of research and signification].
Topics: Bacterial Infections; Diarrhea; Fatty Acids, Volatile; Glutamine; Humans; Ileitis; Inflammation; Met | 1993 |
Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch.
Topics: Adult; Female; Follow-Up Studies; Humans; Incidence; Inflammation; Intestinal Mucosa; Male; Metronid | 1993 |
Evaluation of the inflammatory infiltrate in pouchitis with 111In-labeled granulocytes.
Topics: Acute Disease; Biopsy; Chronic Disease; Gastrointestinal Hemorrhage; Granulocytes; Humans; Indium Ra | 1993 |
[The role of dalacin C in the management of odontogenic inflammations].
Topics: Bacteria, Aerobic; Bacteria, Anaerobic; Clindamycin; Drug Resistance, Microbial; Humans; Inflammatio | 1995 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Colitis, | 1996 |
The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation.
Topics: Acne Vulgaris; Anti-Bacterial Agents; Humans; Inflammation; Linoleic Acid; Metronidazole; Neutrophil | 1998 |
Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Anti-Inflammatory Age | 2001 |
Bypass enteropathy: an inflammatory process in the excluded segment with systemic complications.
Topics: Adult; Albumins; Arthritis; Body Weight; Dermatitis; Diarrhea; Female; Humans; Ileum; Inflammation; | 1977 |
Epizootic of fatal amebiasis among exhibited snakes: epidemiologic, pathologic, and chemotherapeutic considerations.
Topics: Amebiasis; Animals; Animals, Zoo; Emetine; Entamoebiasis; Enteritis; Gastroenteritis; Inflammation; | 1975 |
[The therapy of swimbladder inflammation (renicola sphaerosporosis) of carp].
Topics: Air Sacs; Animals; Antiprotozoal Agents; Carps; Cyclohexanes; Fatty Acids, Unsaturated; Fish Disease | 1992 |
Pouchitis--is it a wastebasket diagnosis?
Topics: Adenomatous Polyposis Coli; Anal Canal; Anastomosis, Surgical; Anti-Inflammatory Agents; Anti-Inflam | 1991 |
The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne.
Topics: Acne Vulgaris; Drug Synergism; Fatty Acids, Monounsaturated; Free Radicals; Humans; Inflammation; Me | 1990 |
Metronidazole in dracunculiasis. A preliminary report.
Topics: Dracunculiasis; Female; Humans; India; Inflammation; Male; Metronidazole; Time Factors | 1970 |
The brown recluse spider bite: controlled evaluation of treatment using the white rabbit as an animal model.
Topics: Animals; Disease Models, Animal; Female; Inflammation; Injections; Injections, Intramuscular; Methyl | 1971 |